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Abstract
Background—The adipocytokine leptin may increase breast cancer risk, while adiponectin may
be protective. We examined the association of the two circulating markers with mammographic
density, a strong predictor of breast cancer risk.
Methods—For 183 premenopausal participants of a nutritional trial, mammograms performed at
baseline, year 1, and year 2 were assessed for densities using a computer-assisted method. Serum
samples obtained at the same time were analyzed for leptin and adiponectin by ELISA. We applied
mixed models to incorporate the repeated measurements while adjusting for confounders including
body mass index (BMI).
Results—At baseline, the mean age of the subjects was 42.6 ± 2.9 years; 40% were of Asian
ancestry. Leptin was lower and adiponectin higher in normal weight than overweight women. Neither
marker was related to absolute breast density. The significant inverse association of leptin with
percent density disappeared when BMI was added to the model. After stratification by weight, percent
density decreased with higher leptin levels in normal weight women, whereas it increased among
overweight subjects. After adjustment for BMI, the positive association between percent density and
adiponectin was greatly reduced and no longer significant.
Conclusions—These results do not support a strong association of leptin or adiponectin with breast
cancer risk as assessed by mammographic density. On the other hand, the findings suggest the
possibility that the inverse association of BMI with breast cancer risk in premenopausal women is
mediated by adipocytokines.
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Introduction
Limited epidemiologic evidence suggests that the adipocytokines leptin and adiponectin are
related to breast cancer development [1;2]. Leptin, a protein produced mainly by adipose tissue,
participates in pro-inflammatory responses, and may stimulate cancer growth [3;4], thereby
mediating the effect of obesity on cancer risk [4]. Despite many null findings, a few studies
reported an increase in breast cancer risk with higher leptin levels [1;5–9]. Interestingly, breast
cancer risk in a study of young US women declined with higher leptin levels [10], a finding
that agrees with the well established protective effect of body mass index (BMI) in
premenopausal women [11]. Adiponectin is the most abundant protein in adipocytes [12;13],
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decreases with higher levels of adipose tissue, and may protect against breast cancer due to its
antiproliferative and anti-inflammatory effects [14]. Several epidemiologic studies suggest that
lower circulating adiponectin confers an elevated breast cancer risk independent of BMI and
leptin [14]. However, a prospective investigation described a non-significant 30% elevated risk
among premenopausal women [15]. Both adipocytokines may affect the production of
estrogens in adipose tissue, possibly through an effect on aromatase activity [16].
Mammographic density, the relative distribution of radiodense tissue to radiolucent fat in the
breast, is a strong predictor of breast cancer risk [17]. A cross-sectional investigation detected
a strong inverse association between leptin and mammographic density in postmenopausal
women. However, given the relation between BMI and leptin, it disappeared after adjustment
for BMI [18]. Similarly, in a study with premenopausal women that classified breast density
into one of four parenchymal patterns, higher leptin levels were associated with less dense
patterns, but the analysis was not adjusted for BMI [19]. As part of a nutritional intervention
study, we assessed mammographic densities and measured serum levels of leptin and
adiponectin in premenopausal women [20;21]. Using these data, we examined the association
of circulating leptin and adiponectin levels with mammographic density.
Methods
Study design
This investigation used data from a nutritional intervention trial [22]. As described elsewhere,
220 premenopausal participants with normal screening mammograms were randomized to a
soy diet or to the control group and 189 women completed 2 years of intervention [22]. Women
were excluded from this study due to use of oral contraceptives or other sex hormones,
diagnosis of cancer, hysterectomy, no intact ovary or no regular menstrual periods, or high soy
intake. As a result of drop-outs, missing mammograms, and the availability of serum, the
current analysis includes 90 intervention and 93 control women. The Institutional Review
Boards of the University of Hawaii approved the study protocol; participants signed informed
consent and gave written permission to use frozen samples for future analyses.
Mammographic data collection
We scanned the mammograms performed at baseline and after 2 years for each woman, and,
if available, also the image for the interim year using a Kodak LS85 Film Digitizer [20]. One
of the authors (GM) performed computer-assisted density assessment [23;24]. All
mammograms for one woman were assessed during the same session, but the reader was
blinded to the group status and the time sequence of the mammograms. The mammographic
measures included the total breast area, the dense area, the nondense area computed as the
difference between total and dense area, and percent density calculated as the ratio of the dense
to the total area. We averaged the values for the right and the left breast. The intraclass
correlation coefficients (ICC) for a sample of 219 duplicate readings were ICC = 0.93 (95%
CI: 0.91–0.95) for the size of the dense areas and ICC = 0.998 (95% CI: 0.997–0.999) for the
total breast area, resulting in an ICC of 0.95 for percent density (95% CI: 0.93–0.96) [20].
Analytical methods
This study made use of existing serum samples that were collected during the 2-year trial period
4–6 days after ovulation as determined by an ovulation kit [22]. Serum levels of leptin and
adiponectin were assessed by double-antibody enzyme-linked-immunosorbent-assay (ELISA)
(R&D Systems, Minneapolis, MN) according to the manufacturer's specifications [21]. The
assay quality was assessed by 49 blinded controls from a pooled sample donated by 10
premenopausal center employees. The mean intra-batch coefficients of variation (CV) for
leptin and adiponectin were 4.6% and 14.0%, whereas inter-batch CVs were 9.5% and 24.9%.
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Statistical analysis
Statistical analyses were performed using the SAS statistical software package version 9.1
(SAS Institute, Inc., Cary, NC). Because the 90 women in the intervention group did not differ
significantly from the 93 women in the control group and no intervention effect on leptin and
adiponectin was observed [21], all subjects were analyzed together. Due to their non-normal
distribution, BMI and leptin were log-transformed. Spearman correlation coefficients (rs) were
computed to assess the relation between markers and breast density measures. After creating
quartiles for the two markers, we computed means of breast density by category using Proc
Mixed in SAS 9.1 [25;26], a procedure that allows for an analysis of repeated measures with
unbalanced times of measurement [27]. To assess significance of the association, we included
the marker as a continuous variable while adjusting for age at mammogram. Ethnicity, parity,
age at first live birth, and BMI were added for further adjustment because of their known
association with breast density. The analyses were repeated after stratification by weight status,
i.e., normal weight with a BMI <25 kg/m2 and overweight with a BMI of ≥25 kg/m2, while
controlling for BMI as a continuous variable.
Results
The study population included 67 Caucasian, 23 Hawaiian, 49 Japanese, 14 Chinese, 11
Filipino, and 19 mixed/other women with substantial differences in BMI and mammographic
measures (Table 1). Mean levels of leptin were significantly lower in Asian than in Caucasian
women (p = 0.002), but the Native Hawaiian/Other group did not differ from Caucasians. On
the other hand, adiponectin was significantly lower in Asian (p = 0.04) and in Hawaiian/Other
women (p = 0.003) than in Caucasians. Mean BMI was significantly lower among Asians than
in the two other groups (p = 0.002). The mean age of the study population was 42.6 ± 2.9 at
the time of the baseline mammogram (Table 2). BMI and the size of the total breast increased
over time, while the dense area and percent density decreased. Leptin and adiponectin were
slightly higher after 2 years. Close to half of the women were overweight or obese and mean
leptin levels were significantly higher in these women than in normal weight (20.8 and 40.4
vs. 10.7 ng/mL; p <0.0001). The relation for adiponectin was reversed; the respective means
for normal weight, overweight and obese women were 9.5, 7.1, and 5.9 μg/mL (p <0.0001).
Leptin and adiponectin were strongly related to BMI (rs = 0.80 for leptin and rs = −0.41 for
adiponectin; both p <0.0001). Percent density was significantly associated with leptin (rs =
−0.48; p <0.0001) and adiponectin (rs = 0.24; p <0.0001), whereas the size of the dense are
was not (rs = −0.04; p = 0.40 and rs = 0.07; p = 0.13). When adjusted means by quartiles of
serum levels were computed (Table 3), both markers were also not related to absolute breast
density. The 5.6% difference in dense area between the top and bottom quartiles of adiponectin
(p = 0.14) was reduced after including other covariates. Leptin was significantly inversely
associated with percent density (p <0.0001) when adjusted only for age, ethnicity, and
reproductive factors with 10% lower densities in the highest vs. the lowest category. However,
this association was attenuated to the null after adjustment for BMI. Percent density increased
from 39.6 to 48.3% from the first to the fourth quartile of adiponectin (p = 0.001). When adding
BMI to the model, this difference was reduced to 4.7% (p = 0.10). When we repeated these
analyses for Asians and Caucasians separately, similar trends were found in both groups (data
not shown).
Stratification by weight status produced no significant differences when the dense area was
modeled (Table 3 and Figure 1). For percent density, the well established difference in densities
was observed; overweight/obese women had approximately 30% lower densities than normal
weight women. The interaction between weight status, i.e., normal vs. overweight/obese, and
leptin levels (p = 0.002) was significant. In the stratified analysis, normal weight women in
the top quartile had 7.4% lower percent densities than those in the bottom quartile (p = 0.005),
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but this association was reversed among overweight women whose percent density was 8.2%
higher in the top than in the bottom category (p = 0.03).
Discussion
These findings among premenopausal women do not support an adverse effect of leptin or a
protective effect of adiponectin on breast cancer risk as assessed by mammographic densities.
In agreement with a previous report among postmenopausal women [18], adjustment for BMI
eliminated the inverse association between leptin and breast density in this population of
premenopausal women. The only previous study among premenopausal women used a
qualitative method of breast density assessment and did not adjust for BMI [19]. Our stratified
analysis suggests that leptin levels may be associated with elevated percent densities among
overweight but not normal weight women. To our knowledge, no previous studies have looked
at adiponectin and breast density. The suggestive positive association of percent density with
adiponectin may be due to residual confounding by adiposity or it may indicate that adiponectin
elevates risk in premenopausal women in contrast to the hypothesized protective effect in
postmenopausal women, just as BMI [11] and possibly leptin [10] have opposite effects on
breast cancer before and after menopause.
In agreement with the protective effect of overweight [11], three case-control studies among
premenopausal women found that leptin was non-significantly associated with a lower breast
cancer risk [6;10;28], whereas other studies described an increased risk with higher leptin levels
in pre-and postmenopausal women [5;7–9]. The adiponectin findings agree with a report from
the Nurses Health Study that described a non-significantly elevated breast cancer risk with
higher adiponectin levels in premenopausal women, while risk was lowered among
postmenopausal women [15]. Given the current evidence, there is more support for a protective
effect of adiponectin in post- than premenopausal women [14]. Our findings of lower
adiponectin levels among Asian than Caucasian women despite lower BMI agree with a study
among Japanese and Caucasian men; the former had lower adiponectin levels despite their
lower BMI [29]. The authors suggest that the higher proportion of visceral adipose tissue as
compared to subcutaneous adipose tissue in Japanese may explain this observation.
This investigation was limited by the strict selection criteria for the original trial that may limit
the generalizability of our findings [22]. We used BMI to adjust for body fat although it is not
a very representative measure across ethnic groups [30]; no other information on adiposity was
available. Therefore, the few suggestive findings may be due to residual confounding by
adiposity. Due to the limited power in subgroups, chance may be responsible for the opposite
directions of the association between percent density and leptin after stratification by weight
status. The small number of subjects in each ethnic group made it impossible to divide the
population into more specific weight categories. On the other hand, the study had several
strengths. We were able to use existing serum samples with excellent control of blood collection
during luteal phase of the menstrual cycle under standardized conditions [22]. The long study
period of 2 years and the availability of more than one observation for each subject were a
great benefit because the study design addressed the intraindividual variability in markers. As
shown by ICCs for leptin and adiponectin of 0.91 and 0.84, respectively, when all five measures
of leptin and adiponectin were used, both markers were quite stable over time [21].
The question of what links adiposity to breast cancer risk has not been answered yet [31], but
this study lends support to the contention that the protective effect of BMI on breast cancer
risk in premenopausal women may be mediated by high leptin/low adiponectin because these
markers were associated with breast density before but not after adjustment for BMI. However,
given the strong correlation between BMI and leptin, it is not possible to disentangle their
separate effects and draw conclusions in such a small study. Nevertheless, the effect of
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adipocytokines on breast cancer risk could be independent of breast density similar to those
shown for circulating hormones [32] and body weight [33].
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Figure 1.
Mean Breast Density for Quartiles of Markers Stratified by Weight Status*
*The cut-off for normal vs. overweight is 25 kg/m2; adjusted for age, ethnicity, reproductive
variables, and BMI
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Table 1
Study Population by Ethnicity at Baseline
Variable Caucasian Asian Hawaiian/Other
Number of women 67 74 42
Percent overweight (BMI 25–<30 kg/m2) 22.4 25.7 33.3
Percent obese (BMI >30 kg/m2) 25.4 14.9 31.0
Mean (SD)
Age at mammogram (y) 42.3 (2.9) 43.0 (2.7) 42.2 (3.3)
Body mass index (kg/m2) 27.0 (6.8) 24.6 (4.4) 27.4 (5.4)
Total breast area (cm2) 130 (71) 83 (42) 112 (43)
Dense area (cm2) 45 (29) 36 (20) 64 (43)
Nondense area (cm2) 86 (72) 47 (41) 64 (43)
Percent density (%) 41.1 (23.8) 48.7 (24.9) 48.1 (24.1)
Leptin (ng/mL) 23.4 (18.5) 14.8 (10.8) 20.5 (15.0)
Adiponectin (μg/mL) 9.4 (4.2) 7.5 (3.7) 6.7 (3.0)
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Table 2
Characteristics of 183 Study Participants over 2 Years
Variable Baseline Year 1 Year 2
Number of women 183 96 166
Percent overweight (BMI 25–<30 kg/m2) 26.2 29.2 30.7
Percent obese (BMI >30 kg/m2) 22.4 22.9 19.3
Mean (SD)
Age at mammogram (y) 42.6 (2.9) 44.0 (2.8) 45.0 (2.8)
Body mass index (kg/m2) 26.1 (5.7) 26.5 (6.2) 26.5 (6.2)
Total breast area (cm2) 106.9 (58.0) 110.6 (64.8) 110.8 (62.3)
Dense area (cm2) 41.9 (25.1) 41.4 (27.6) 40.4 (25.9)
Nondense area (cm2) 65.1 (57.2) 69.2 (62.7) 70.4 (60.9)
Percent density (%) 45.8 (24.5) 45.0 (26.6) 42.5 (24.0)
Leptin (ng/mL) 19.3 (15.4) 20.7 (15.8) 20.2 (16.6)
Adiponectin (μg/mL) 8.0 (3.9) 7.9 (3.9) 8.2 (3.9)
Eur J Cancer Prev. Author manuscript; available in PMC 2011 January 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Maskarinec et al. Page 10
Ta
bl
e 
3
M
ea
n 
M
am
m
og
ra
ph
ic
 D
en
si
ty
 b
y 
Q
ua
rti
le
s o
f A
di
po
cy
to
ki
ne
s
M
od
el
Q
ua
rt
ile
s o
f l
ep
tin
 (n
g/
m
L
)^
P 
fo
r 
tr
en
d
0.
9–
8.
4
8.
5–
15
.6
15
.7
–2
6.
2
26
.3
–8
8.
0
D
en
se
 a
re
a 
(c
m
2 )
 
A
dj
us
te
d 
fo
r a
ge
40
.2
 (2
.4
)
40
.5
 (2
.2
)
41
.4
 (2
.2
)
42
.3
 (2
.4
)
0.
98
 
Pa
rti
al
ly
 a
dj
us
te
d*
41
.7
 (2
.4
)
41
.7
 (2
.2
)
42
.1
 (2
.2
)
42
.5
 (2
.4
)
0.
53
 
Fu
lly
 a
dj
us
te
d#
40
.3
 (2
.5
)
41
.1
 (2
.2
)
42
.8
 (2
.2
)
44
.2
 (2
.5
)
0.
60
 
 
N
or
m
al
 w
ei
gh
t
42
.0
 (2
.1
)
41
.7
 (2
.1
)
39
.6
 (2
.6
)
39
.6
 (3
.6
)
0.
12
 
 
O
ve
rw
ei
gh
t
36
.4
 (5
.2
)
39
.1
 (4
.0
)
41
.0
 (3
.4
)
45
.5
 (3
.4
)
0.
22
Pe
rc
en
t d
en
si
ty
 (%
)
 
A
dj
us
te
d 
fo
r a
ge
49
.4
 (2
.2
)
46
.5
 (2
.0
)
42
.3
 (2
.0
)
38
.7
 (2
.2
)
<0
.0
00
1
 
Pa
rti
al
ly
 a
dj
us
te
d*
49
.9
 (2
.2
)
46
.8
 (2
.1
)
43
.1
 (2
.1
)
39
.5
 (2
.3
)
<0
.0
00
1
 
Fu
lly
 a
dj
us
te
d#
45
.5
 (2
.1
)
44
.7
 (1
.9
)
45
.2
 (1
.9
)
45
.1
 (2
.2
)
0.
31
 
 
N
or
m
al
 w
ei
gh
t
59
.1
 (2
.5
)
56
.0
 (2
.4
)
53
.4
 (3
.2
)
51
.7
 (4
.6
)
0.
00
5
 
 
O
ve
rw
ei
gh
t
26
.7
 (3
.5
)
29
.8
 (2
.7
)
32
.6
 (2
.3
)
34
.9
 (2
.3
)
0.
03
Q
ua
rt
ile
s o
f a
di
po
ne
ct
in
 (μ
g/
m
L
)
0.
7–
4.
8
4.
9–
7.
5
7.
6–
10
.2
10
.3
–2
4.
5
D
en
se
 a
re
a 
(c
m
2 )
 
A
dj
us
te
d 
fo
r a
ge
37
.6
 (2
.4
)
40
.0
 (2
.1
)
43
.7
 (2
.1
)
43
.2
 (2
.3
)
0.
14
 
Pa
rti
al
ly
 a
dj
us
te
d*
38
.6
 (2
.4
)
41
.0
 (2
.1
)
44
.7
 (2
.1
)
44
.2
 (2
.3
)
0.
14
 
Fu
lly
 a
dj
us
te
d#
38
.9
 (2
.4
)
41
.2
 (2
.1
)
44
.6
 (2
.2
)
43
.9
 (2
.3
)
0.
26
 
 
N
or
m
al
 w
ei
gh
t
38
.3
 (2
.8
)
40
.4
 (2
.3
)
41
.9
 (2
.1
)
43
.0
 (2
.2
)
0.
30
 
 
O
ve
rw
ei
gh
t
38
.9
 (3
.6
)
43
.7
 (3
.3
)
46
.0
 (3
.6
)
43
.9
 (4
.0
)
0.
28
Pe
rc
en
t d
en
si
ty
 (%
)
 
A
dj
us
te
d 
fo
r a
ge
39
.6
 (2
.3
)
42
.7
 (2
.0
)
46
.0
 (2
.0
)
48
.3
 (2
.2
)
0.
00
1
 
Pa
rti
al
ly
 a
dj
us
te
d*
40
.0
 (2
.3
)
43
.3
 (2
.0
)
46
.7
 (2
.0
)
49
.1
 (2
.2
)
0.
00
07
 
Fu
lly
 a
dj
us
te
d#
42
.5
 (2
.1
)
44
.4
 (1
.8
)
46
.5
 (1
.8
)
47
.2
 (2
.0
)
0.
10
 
 
N
or
m
al
 w
ei
gh
t
51
.9
 (3
.4
)
55
.5
 (2
.7
)
56
.4
 (2
.5
)
59
.8
 (2
.6
)
0.
14
Eur J Cancer Prev. Author manuscript; available in PMC 2011 January 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Maskarinec et al. Page 11
Q
ua
rt
ile
s o
f a
di
po
ne
ct
in
 (μ
g/
m
L
)
0.
7–
4.
8
4.
9–
7.
5
7.
6–
10
.2
10
.3
–2
4.
5
 
 
O
ve
rw
ei
gh
t
30
.2
 (2
.4
)
33
.4
 (2
.2
)
35
.9
 (2
.4
)
33
.4
 (2
.7
)
0.
17
* A
dj
us
te
d 
fo
r a
ge
, e
th
ni
ci
ty
, p
ar
ity
, a
nd
 a
ge
 a
t f
irs
t l
iv
e 
bi
rth
# A
dj
us
te
d 
fo
r a
ge
, e
th
ni
ci
ty
, p
ar
ity
, a
ge
 a
t f
irs
t l
iv
e 
bi
rth
, a
nd
 B
M
I
^ M
ea
ns
 a
nd
 st
an
da
rd
 e
rr
or
s a
re
 sh
ow
n
Eur J Cancer Prev. Author manuscript; available in PMC 2011 January 1.
